Twist Bioscience Co. (NASDAQ:TWST) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have received an average recommendation of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $54.40.

A number of equities research analysts have issued reports on the stock. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday, February 4th. TD Cowen reissued a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Wolfe Research assumed coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Finally, Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th.

Twist Bioscience Price Performance

TWST stock opened at $42.05 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience has a 52 week low of $27.41 and a 52 week high of $60.90. The firm’s fifty day moving average is $47.05 and its 200 day moving average is $45.54. The firm has a market cap of $2.51 billion, a P/E ratio of -12.44 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.75) EPS. Research analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 5,886 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the sale, the chief financial officer now owns 110,096 shares of the company’s stock, valued at $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 2,216 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $116,783.20. Following the sale, the chief executive officer now directly owns 674,718 shares in the company, valued at $35,557,638.60. The trade was a 0.33 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,676 shares of company stock worth $1,640,289 over the last 90 days. 3.01% of the stock is owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in Twist Bioscience during the fourth quarter worth about $58,000. Westwood Holdings Group Inc. bought a new stake in Twist Bioscience during the fourth quarter worth about $657,000. Teza Capital Management LLC bought a new position in shares of Twist Bioscience in the fourth quarter worth approximately $204,000. Sherbrooke Park Advisers LLC bought a new position in shares of Twist Bioscience in the fourth quarter worth approximately $238,000. Finally, ProShare Advisors LLC lifted its stake in shares of Twist Bioscience by 30.5% in the fourth quarter. ProShare Advisors LLC now owns 19,226 shares of the company’s stock worth $893,000 after buying an additional 4,488 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.